Description

Atara Biotherapeutics, Inc., founded in 2012 and headquartered in South San Francisco, California, is a biopharmaceutical company focused on developing readily available ("off-the-shelf") T-cell immunotherapies. Their primary objective is to create treatments for patients battling cancer, autoimmune, and viral diseases, with a focus on the United States market. The company's lead investigational therapy, tabelecleucel, is a T-cell immunotherapy currently undergoing Phase 3 clinical trials. This treatment is being developed for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease (PTLD), as well as a range of hematologic and solid tumors, including nasopharyngeal carcinoma. In addition to tabelecleucel, Atara is advancing a pipeline of next-generation CAR T immunotherapies. These are designed to address both hematologic malignancies and solid tumors, featuring candidates such as ATA2271 and ATA3271 for mesothelin targets, and ATA2431 and ATA3219 for B-cell malignancies. The company also has ATA188 in development for the treatment of multiple sclerosis and the ATA368 program targeting human papillomavirus (HPV)-associated cancers. To support its extensive research and development efforts, Atara Biotherapeutics has established key partnerships and licensing agreements. These collaborations include Memorial Sloan Kettering Cancer Center, a research and development and licensing agreement with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Furthermore, Atara is collaborating with Bayer AG on the development of mesothelin-targeted CAR T-cell therapies specifically for solid tumors.